Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control

Summary

Connective tissue diseases (CTD) or systemic autoimmune diseases (SADs) as they are known today are a group of chronic inflammatory conditions with autoimmune aetiology with few treatment options and difficult diagnosis.Brest team contribute to perform a new classification of the following systemic autoimmune diseases in a European Union's Seventh Framework Programme. The aim of this research is to constitute a Healthy Volunteers cohort to compare with systemic autoimmune diseases cohort into molecular clusters instead of clinical entities through the determination of molecular profiles using several "Omics" techniques.

Conditions

• Healthy Subjects

Sponsors & Collaborators

• UCB Biopharma S.P.R.L.

  collaborator INDUSTRY

• Atrys Health

  collaborator INDUSTRY

• National Research Council, Spain

  collaborator OTHER_GOV

• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

  collaborator OTHER

• Servicio Cántabro de Salud

  collaborator OTHER

• August Pi Sunyer Biomedical Research Institute

  collaborator OTHER

• Karolinska Institutet

  collaborator OTHER

• KU Leuven

  collaborator OTHER

• Klinikum der Universität Köln

  collaborator OTHER

• Hannover Medical School

  collaborator OTHER

• Medical University of Vienna

  collaborator OTHER

• Quartz Bio S.A.

  collaborator OTHER

• Andaluz Health Service

  collaborator OTHER_GOV

• The Cyprus Foundation for Muscular Dystrophy Research

  collaborator OTHER

• Universidad de Granada

  collaborator OTHER

• University of Milan

  collaborator OTHER

• Université Catholique de Louvain

  collaborator OTHER

• University Hospital, Brest

  collaborator OTHER

• University of Geneva, Switzerland

  collaborator OTHER

• Szeged University

  collaborator OTHER

• Bayer

  collaborator INDUSTRY

• Institut de Recherches Internationales Servier

  collaborator OTHER

• Sanofi

  collaborator INDUSTRY

• Eli Lilly and Company

  collaborator INDUSTRY

• Charite University, Berlin, Germany

  collaborator OTHER

• Centro Hospitalar do Porto

  collaborator OTHER

• Institut d'Investigació Biomèdica de Bellvitge

  collaborator OTHER

• Innovative Medicines Initiative

  collaborator OTHER

• Fundación Pública Andaluza Progreso y Salud

  lead OTHER

Principal Investigators

• Marta Alarcon · Fundación Pública Andaluza Progreso y Salud (PHFSpain)

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-12-31

Primary Completion

2017-10-31

Completion

2017-10-31

Countries

• Austria
• Belgium
• France
• Germany
• Hungary
• Italy
• Portugal
• Spain
• Switzerland

Study Locations